US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

ADMA Biologics Inc - Common Stock (NQ:ADMA)

9.720 -0.210 (-2.11%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
ADMA Fraud Notice: ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop — BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA Biologics, Inc. – ADMA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
News headline image
The Great Rotation of 2026: Why Small Caps are Finally Dethroning the Tech Giants
The financial landscape of 2026 has been defined by a seismic shift in capital allocation that few analysts predicted with such intensity. For the first time in over a decade, the long-dormant Russell... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Why Are Shares Of ADMA Biologics Falling Today? ↗
ADMA Biologics, Inc. (NASDAQ: ADMA) shares are tumbling on Thursday as traders lean into risk-off positioning and punish weaker charts in a down tape. The Nasdaq is down 0.91% while the S&P 500 has... 
Via Benzinga
Topics Stocks
News headline image
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ADMA Biologics Addresses Misleading Short-Seller Report
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline. 
Via The Motley Fool
News headline image
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript ↗
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >